Revolutionizing Personalized Diagnostics and Global Health with Jari Närhi, Co-Founder of NADMed

This week on Tech Can’t Save Us, host Paul David is joined by Jari Närhi, Co-Founder of NADMed, a Finnish health technology company that is redefining personalized diagnostics and global health. NADMed has developed a breakthrough method for extracting and measuring nicotinamide adenine dinucleotides (NADs)—critical biomarkers for metabolic health, aging, and disease management.

They discuss how the medical landscape is transitioning from the age of genomics into the age of metabolism. Jari explains the fundamental role NADs play in cell-level metabolism and regulating hundreds of metabolic processes. He highlights how NADMed has revolutionized the field by shrinking a process that previously required million-dollar mass spectrometry machines and weeks of waiting into a simple, rapid kit that clinical laboratories can use to get results in hours.

The conversation covers the challenges of scaling a global medtech brand from Finland, including navigating complex regulatory paths like the FDA’s de novo pathway and educating the broader medical community on metabolic measurement. Jari also shares key insights from his 30-year leadership journey across information security and healthcare tech, explaining his philosophy on capital efficiency through strategic research partnerships and why honesty, trust, and respect remain universal leadership truths.

Find more about NADMed here: https://www.nadmed.com/ 
Follow Jari Närhi here: https://www.linkedin.com/in/jari-n%C3%A4rhi-38b44/?skipRedirect=true